US Amjevita Sales Slide By Almost Two-Thirds

Amgen’s Humira Biosimilar Turnover Slides In US Ahead Of Fresh Wave Of Launches

 
• By Dave Wallace

Amgen has revealed a significant – albeit expected – drop in second-quarter sales figures for its Amjevita US biosimilar rival to Humira.

Amgen logo syringe vials
Amgen saw US sales of its Humira biosimilar drop by nearly two-thirds in Q2 • Source: Shutterstock

More from Biosimilars

More from Products